Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FH535 |
Synonyms | |
Therapy Description |
FH535 is PPAR antagonist and Wnt/CTNNB1 pathway inhibitor, which prevents cell proliferation (PMID: 18347139, PMID: 32681102). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FH535 | CTNNB1 Inhibitor 27 | FH535 is PPAR antagonist and Wnt/CTNNB1 pathway inhibitor, which prevents cell proliferation (PMID: 18347139, PMID: 32681102). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colon carcinoma | sensitive | FH535 | Preclinical | Actionable | In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139). | 18347139 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|